Delcath Systems, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DCTH research report →
Companywww.delcath.com
Delcath Systems, Inc. , an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- CEO
- Gerard J. Michel
- IPO
- 2018
- Employees
- 96
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $387.68M
- P/E
- 721.07
- P/S
- 4.29
- P/B
- 3.59
- EV/EBITDA
- 1071.83
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 85.97%
- Op Margin
- -1.79%
- Net Margin
- 0.62%
- ROE
- 0.51%
- ROIC
- -0.59%
Growth & Income
- Revenue
- $85.23M · 129.08%
- Net Income
- $2.70M · 110.23%
- EPS
- $0.08 · 108.15%
- Op Income
- $660.00K
- FCF YoY
- 208.99%
Performance & Tape
- 52W High
- $18.19
- 52W Low
- $8.12
- 50D MA
- $10.26
- 200D MA
- $10.20
- Beta
- 0.54
- Avg Volume
- 398.82K
Get TickerSpark's AI analysis on DCTH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Sylvester John Richard | other | 22,500 |
| May 13, 26 | Martell Bridget A | other | 22,500 |
| May 13, 26 | CZEREPAK ELIZABETH | other | 22,500 |
| May 13, 26 | SALAMON STEVEN A J | other | 22,500 |
| May 13, 26 | Aharon Gil | other | 22,500 |
| Mar 6, 26 | Pennell Sandra | buy | 5,533 |
| Mar 2, 26 | MICHEL GERARD J | buy | 11,200 |
| Feb 17, 26 | Hoffman David L. | other | 56,500 |
| Feb 17, 26 | Hoffman David L. | other | 28,250 |
| Feb 17, 26 | Muir Kevin | other | 56,500 |
Our DCTH Coverage
We haven't published any research on DCTH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DCTH Report →